Which has better earnings and valuation, KPTI or VOR?

Vor Biopharma has lower revenue, but higher earnings than Karyopharm Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Karyopharm Therapeutics $146.07M 1.32 -$196.04M -$15.09 N/A Vor Biopharma N/A N/A N/A N/A N/A

Is KPTI or VOR more profitable?

Vor Biopharma has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics -129.02% N/A -120.29% Vor Biopharma N/A N/A N/A

Does the media prefer KPTI or VOR?

In the previous week, Karyopharm Therapeutics had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 5 mentions for Karyopharm Therapeutics and 3 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.24 beat Karyopharm Therapeutics' score of 0.00 indicating that Vor Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Karyopharm Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vor Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is LBRX or KPTI more profitable?

LB Pharmaceuticals has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Company Net Margins Return on Equity Return on Assets LB Pharmaceuticals N/A N/A N/A Karyopharm Therapeutics -129.02% N/A -120.29%

Does the media favor CYRX or KPTI?

In the previous week, Karyopharm Therapeutics had 3 more articles in the media than CryoPort. MarketBeat recorded 5 mentions for Karyopharm Therapeutics and 2 mentions for CryoPort. CryoPort's average media sentiment score of 0.34 beat Karyopharm Therapeutics' score of 0.00 indicating that CryoPort is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Karyopharm Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Karyopharm Therapeutics (KPTI) Competitors

$8.50 -0.58 (-6.39%)

Closing price 04:00 PM Eastern

Extended Trading

$8.52 +0.03 (+0.29%)

As of 06:43 PM Eastern

Compare

KPTI vs. VOR, ESPR, LBRX, CYRX, and AURA

Should you buy Karyopharm Therapeutics stock or one of its competitors? MarketBeat compares Karyopharm Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Karyopharm Therapeutics include Vor Biopharma (VOR), Esperion Therapeutics (ESPR), LB Pharmaceuticals (LBRX), CryoPort (CYRX), and Aura Biosciences (AURA). These companies are all part of the "pharmaceutical products" industry.

How does Karyopharm Therapeutics compare to Vor Biopharma?

Karyopharm Therapeutics (NASDAQ:KPTI) and Vor Biopharma (NASDAQ:VOR) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

Vor Biopharma has lower revenue, but higher earnings than Karyopharm Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	1.32	-$196.04M	-$15.09	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Vor Biopharma has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-129.02%	N/A	-120.29%
Vor Biopharma	N/A	N/A	N/A

Karyopharm Therapeutics currently has a consensus target price of $17.17, indicating a potential upside of 101.96%. Vor Biopharma has a consensus target price of $42.25, indicating a potential upside of 217.91%. Given Vor Biopharma's higher probable upside, analysts clearly believe Vor Biopharma is more favorable than Karyopharm Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are owned by institutional investors. 1.7% of Karyopharm Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Vor Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Karyopharm Therapeutics had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 5 mentions for Karyopharm Therapeutics and 3 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.24 beat Karyopharm Therapeutics' score of 0.00 indicating that Vor Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Karyopharm Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vor Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Karyopharm Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market.

Summary

Vor Biopharma beats Karyopharm Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Esperion Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

In the previous week, Karyopharm Therapeutics had 5 more articles in the media than Esperion Therapeutics. MarketBeat recorded 5 mentions for Karyopharm Therapeutics and 0 mentions for Esperion Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.00 equaled Esperion Therapeutics'average media sentiment score.

Company	Overall Sentiment
Karyopharm Therapeutics	Neutral
Esperion Therapeutics	Neutral

Esperion Therapeutics has a net margin of 0.12% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Esperion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-129.02%	N/A	-120.29%
Esperion Therapeutics	0.12%	-0.14%	0.12%

Esperion Therapeutics has higher revenue and earnings than Karyopharm Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	1.32	-$196.04M	-$15.09	N/A
Esperion Therapeutics	$403.14M	2.01	-$22.68M	-$0.06	N/A

Karyopharm Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

Karyopharm Therapeutics presently has a consensus target price of $17.17, suggesting a potential upside of 101.96%. Esperion Therapeutics has a consensus target price of $5.54, suggesting a potential upside of 75.87%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Karyopharm Therapeutics is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are held by institutional investors. 1.7% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 1.6% of Esperion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Karyopharm Therapeutics beats Esperion Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to LB Pharmaceuticals?

LB Pharmaceuticals (NASDAQ:LBRX) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

In the previous week, Karyopharm Therapeutics had 5 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 5 mentions for Karyopharm Therapeutics and 0 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 0.00 equaled Karyopharm Therapeutics'average media sentiment score.

Company	Overall Sentiment
LB Pharmaceuticals	Neutral
Karyopharm Therapeutics	Neutral

LB Pharmaceuticals has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	N/A	N/A
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 5.8% of LB Pharmaceuticals shares are owned by company insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

LB Pharmaceuticals currently has a consensus target price of $38.40, indicating a potential upside of 30.61%. Karyopharm Therapeutics has a consensus target price of $17.17, indicating a potential upside of 101.96%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

LB Pharmaceuticals has higher earnings, but lower revenue than Karyopharm Therapeutics. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A
Karyopharm Therapeutics	$146.07M	1.32	-$196.04M	-$15.09	N/A

Summary

LB Pharmaceuticals and Karyopharm Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to CryoPort?

CryoPort (NASDAQ:CYRX) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

CryoPort has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

92.9% of CryoPort shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 10.1% of CryoPort shares are held by company insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

CryoPort currently has a consensus price target of $15.11, indicating a potential downside of 2.38%. Karyopharm Therapeutics has a consensus price target of $17.17, indicating a potential upside of 101.96%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Karyopharm Therapeutics is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Karyopharm Therapeutics had 3 more articles in the media than CryoPort. MarketBeat recorded 5 mentions for Karyopharm Therapeutics and 2 mentions for CryoPort. CryoPort's average media sentiment score of 0.34 beat Karyopharm Therapeutics' score of 0.00 indicating that CryoPort is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Karyopharm Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CryoPort has higher revenue and earnings than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.43	$78.30M	$1.35	11.47
Karyopharm Therapeutics	$146.07M	1.32	-$196.04M	-$15.09	N/A

CryoPort has a net margin of 41.57% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

Summary

CryoPort beats Karyopharm Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Aura Biosciences?

Karyopharm Therapeutics (NASDAQ:KPTI) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

Aura Biosciences has lower revenue, but higher earnings than Karyopharm Therapeutics. Aura Biosciences is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	1.32	-$196.04M	-$15.09	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

Karyopharm Therapeutics currently has a consensus target price of $17.17, indicating a potential upside of 101.96%. Aura Biosciences has a consensus target price of $20.50, indicating a potential upside of 216.36%. Given Aura Biosciences' higher probable upside, analysts clearly believe Aura Biosciences is more favorable than Karyopharm Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Aura Biosciences has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-129.02%	N/A	-120.29%
Aura Biosciences	N/A	-78.12%	-64.08%

66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 1.7% of Karyopharm Therapeutics shares are held by company insiders. Comparatively, 6.3% of Aura Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Karyopharm Therapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

In the previous week, Karyopharm Therapeutics had 5 more articles in the media than Aura Biosciences. MarketBeat recorded 5 mentions for Karyopharm Therapeutics and 0 mentions for Aura Biosciences. Karyopharm Therapeutics' average media sentiment score of 0.00 equaled Aura Biosciences'average media sentiment score.

Company	Overall Sentiment
Karyopharm Therapeutics	Neutral
Aura Biosciences	Neutral

Summary

Karyopharm Therapeutics and Aura Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

Get Karyopharm Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KPTI vs. The Competition

Export

Metric	Karyopharm Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$205.78M	$2.94B	$6.43B	$12.05B
Dividend Yield	N/A	1.69%	2.67%	5.56%
P/E Ratio	-0.56	17.68	23.75	23.75
Price / Sales	1.32	296.71	479.99	83.74
Price / Cash	N/A	56.17	26.99	37.25
Price / Book	-0.53	3.83	10.28	6.78
Net Income	-$196.04M	$75.85M	$3.57B	$337.51M
7 Day Performance	-13.44%	-4.52%	-1.43%	-2.72%
1 Month Performance	-1.62%	-5.85%	3.27%	1.87%
1 Year Performance	89.31%	15.31%	23.37%	26.61%

Karyopharm Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KPTI Karyopharm Therapeutics	2.1958 of 5 stars	$8.50 -6.4%	$17.17 +102.0%	+102.2%	$205.78M	$146.07M	N/A	380
VOR Vor Biopharma	2.9824 of 5 stars	$14.57 -2.7%	$42.25 +190.0%	N/A	$811.16M	N/A	N/A	140	News Coverage Gap Up
ESPR Esperion Therapeutics	3.5491 of 5 stars	$3.13 flat	$5.54 +77.0%	+156.6%	$805.76M	$403.14M	N/A	200
LBRX LB Pharmaceuticals	1.7844 of 5 stars	$28.03 +0.2%	$38.40 +37.0%	N/A	$802.09M	N/A	N/A	16
CYRX CryoPort	3.392 of 5 stars	$15.99 +1.9%	$14.69 -8.1%	+124.3%	$790.81M	$182.94M	11.84	1,186	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KPTI) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Karyopharm Therapeutics (KPTI) Competitors

KPTI vs. VOR, ESPR, LBRX, CYRX, and AURA

How does Karyopharm Therapeutics compare to Vor Biopharma?

Summary

How does Karyopharm Therapeutics compare to Esperion Therapeutics?

Summary

How does Karyopharm Therapeutics compare to LB Pharmaceuticals?

Summary

How does Karyopharm Therapeutics compare to CryoPort?

Summary

How does Karyopharm Therapeutics compare to Aura Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI vs. The Competition

Karyopharm Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Karyopharm Therapeutics (KPTI) Competitors

KPTI vs. VOR, ESPR, LBRX, CYRX, and AURA

How does Karyopharm Therapeutics compare to Vor Biopharma?

Which has better earnings and valuation, KPTI or VOR?

Is KPTI or VOR more profitable?

Do analysts rate KPTI or VOR?

Do institutionals & insiders believe in KPTI or VOR?

Does the media prefer KPTI or VOR?

Which has more risk and volatility, KPTI or VOR?

Summary

How does Karyopharm Therapeutics compare to Esperion Therapeutics?

Does the media refer more to KPTI or ESPR?

Is KPTI or ESPR more profitable?

Which has better valuation and earnings, KPTI or ESPR?

Which has more risk & volatility, KPTI or ESPR?

Do analysts rate KPTI or ESPR?

Do institutionals and insiders hold more shares of KPTI or ESPR?

Summary

How does Karyopharm Therapeutics compare to LB Pharmaceuticals?

Does the media favor LBRX or KPTI?

Is LBRX or KPTI more profitable?

Do insiders & institutionals believe in LBRX or KPTI?

Do analysts prefer LBRX or KPTI?

Which has better earnings and valuation, LBRX or KPTI?

Summary

How does Karyopharm Therapeutics compare to CryoPort?

Which has more risk & volatility, CYRX or KPTI?

Do insiders and institutionals believe in CYRX or KPTI?

Do analysts recommend CYRX or KPTI?

Does the media favor CYRX or KPTI?

Which has stronger earnings & valuation, CYRX or KPTI?

Is CYRX or KPTI more profitable?

Summary

How does Karyopharm Therapeutics compare to Aura Biosciences?

Which has stronger valuation & earnings, KPTI or AURA?

Do analysts rate KPTI or AURA?

Is KPTI or AURA more profitable?

Do institutionals and insiders believe in KPTI or AURA?

Which has more volatility & risk, KPTI or AURA?

Does the media refer more to KPTI or AURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI vs. The Competition

Karyopharm Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools